Genekam Biotechnology AG

First commercial test for detection of virulence (dangerous) birdflu influenza viruses

First commercial test for detection of virulence (dangerous) birdflu influenza viruses

Genekam Biotechnology AG has developed a test, which can detect the virulence strains of influenza viruses particularly H5N1 known as birdflu. It will be available under the trade name: Fluhunter. It can function with nasal swabs and respiratory swabs.

There are two kinds of influenza viruses strains: highly pathogenic, which cause outbreaks and low pathogenic stains or nonvirulence strains, which does not cause outbreaks, hence it is essential to have such test, which can let the laboratory know whether the tested sample has highly pathogenic (virulent strain) or low pathogenic (virulent). At present, reference laboratories have only the methodology to check whether a sample has virulent strain or not as they run a tests, which may need many days to predict the virulence of the strains. On the market, there are a number of tests available for detection influenza virus H5N1, but non of them can differentiate such virulence strains. The costs of Genekam test is Euro 6 per reaction, it means that even the poorest countries of the world can use this test. The results will be available within 3-4 hours.

Genekam Biotechnology AG is a German company working medical biotechnological solutions particularly detection , prevention and therapy development of viruses. It sells its products in 70 countries around the world.

Further information:

Genekam Biotechnology AG
Duissernstr. 65a
47058 Duisburg

Tel. 0203-55585811
Fax 0203-358299
e-mail: anfrage@genekam.de